Benzinga | Aug 16, 2021 06:36AM EDT

HC Wainwright & Co. Maintains Neutral on Aprea Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Andrew Fein maintains Aprea Therapeutics (NASDAQ:APRE) with a Neutral and lowers the price target from $6 to $4.